This Ipamorelin + Mod GRF(1-29) peptide blend contains 1.5 mg of Ipamorelin and 0.6 mg of Mod GRF(1-29), creating a dual-component research tool for studying pituitary signaling and growth hormone release patterns in controlled laboratory environments. Ipamorelin is a selective GHSR agonist frequently used to examine ghrelin-like receptor activity and targeted GH release without broad endocrine effects. Mod GRF(1-29), also known as CJC without DAC, is widely evaluated for its role in pulsatile GHRH stimulation and receptor-driven GH-axis signaling.
Researchers value this combination for its ability to model coordinated GH regulation using two mechanistically distinct peptides. By combining a selective growth hormone secretagogue with a stabilized GHRH analogue, this blend enables detailed assessment of timing, amplitude, and pathway specificity during GH-pulse stimulation studies.
Common research applications include:
Examining pituitary GH secretion under dual-peptide stimulation
Mapping receptor-driven GH-axis signaling cascades
Studying synergistic endocrine pathway activation
Comparing single-compound versus combination effects
The Ipamorelin + Mod GRF(1-29) peptide blend supports reproducible mechanistic work by offering consistent performance and controlled dosing characteristics. Because each peptide contributes defined signaling behavior, the blend assists researchers in generating clear, interpretable data across repeated trials.
This blend is supplied as a high-purity laboratory reagent for use exclusively by qualified scientific professionals. It is not approved for human or veterinary administration, therapeutic use, clinical application, or diagnostic intent. All handling must follow appropriate institutional safety procedures and regulatory requirements for investigational endocrine materials.
For research use only. Not for human consumption.
Not a researcher? Exit
